Lucentis/Lucentis PFS

Neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (branch or central RVO) & choroidal neovascularization (CNV); proliferative diabetic retinopathy (PDR) in adults. Retinopathy of prematurity (ROP) w/ zone 1 (stage 1+, 2+, 3 or 3+), zone 2 (stage 3+) or AP-ROP (aggressive posterior ROP) disease in preterm infants.

Adult 0.3 mg or 0.5 mg mthly as single intravitreal inj. The interval between 2 doses should not be <1 mth. Max: 0.5 mg. Only 1 eye should be injected on each occasion & post-inj monitoring is recommended. PDR 0.5 mg. Wet AMD, DME, PDR, macular edema secondary to RVO, CNV or CNV secondary to pathologic myopia (PM) Treatment should be given mthly until visual acuity is achieved &/or there no signs of disease activity. Initially ≥3 consecutive mthly inj may be needed for wet AMD, DME, PDR & RVO. May extend treatment interval by 2 wk at a time for wet AMD or by 1 mth at a time for DME. Concomitant therapy w/ laser photocoagulation in DME & branch RVO When given on the same day, administer Lucentis at least 30 min after laser photocoagulation. Preterm infant ROP 0.2 mg as single intravitreal inj. May be given bilaterally on the same day. The interval between 2 doses injected into the same eye should be at least 4 wk.

Hypersensitivity. Patients w/ active or suspected ocular or periocular infections; active intraocular inflammation.

Other Eye Preparations

S01LA04 - ranibizumab ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.

POM